Boehringer Ingelheim
Polo-like kinase 1 (PLK1) plays a role in several important steps in the cell cycle,1,2 including:
In cancer, PLK1 can be overexpressed. In many tumors, this may correlate with a poor prognosis.2 Inhibition of PLK1, which may result in “Polo arrest,” is a focus of anticancer research.1,3 Polo arrest is a uniquephenotype associated with:
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.